Ciombor, K. K., Zemla, T. J., Hubbard, J. M., Jia, J., Gbolahan, O. B., Sousa, A., … Bekaii-Saab, T. S. (2023). A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41, pp. 139–139).

Ciombor, Kristen Keon, Tyler J. Zemla, Joleen M. Hubbard, Jingquan Jia, Olumide B. Gbolahan, Andrea Sousa, Luke Wilson, et al. “A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.” In JOURNAL OF CLINICAL ONCOLOGY, 41:139–139, 2023.

Ciombor KK, Zemla TJ, Hubbard JM, Jia J, Gbolahan OB, Sousa A, et al. A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations. In: JOURNAL OF CLINICAL ONCOLOGY. 2023. p. 139–139.

Ciombor, Kristen Keon, et al. “A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023, pp. 139–139.

Ciombor KK, Zemla TJ, Hubbard JM, Jia J, Gbolahan OB, Sousa A, Wilson L, Waechter B, Ou F-S, Nixon AB, Bekaii-Saab TS. A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations. JOURNAL OF CLINICAL ONCOLOGY. 2023. p. 139–139.